CD19 and acute lymphoblastic leukemia: The success of CAR T‐cell treatment has resulted in FDA approvals for two CAR T‐cell therapies, including CD19 CAR T‐cell therapies for the treatment of children and adolescents with acute lymphoblastic leukaemia (ALL) and adults with relapsed‐refractory large B‐cell lymphoma in 2017.